An in vitro study showed that the inhibition of CTLA-4 receptors by ipilimumab has an impact on the release of IL-2 by tumor cells simultaneously regulating the tumor microenvironment and increasing the immune response [55]. This evidence concerns the gene IL2 and neoplasm.